IMMX (Immix Biopharma) 3-Year EPS without NRI Growth Rate : 28.70% (As of Dec. 2024)

View and export this data going back to 2021. Start your Free Trial

What is Immix Biopharma 3-Year EPS without NRI Growth Rate?

Immix Biopharma's EPS without NRI for the three months ended in Dec. 2024 was $-0.16.

During the past 3 years, the average EPS without NRI Growth Rate was 28.70% per year. During the past 5 years, the average EPS without NRI Growth Rate was -54.80% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EPS without NRI growth rate.

During the past 6 years, the highest 3-Year average EPS without NRI Growth Rate of Immix Biopharma was 28.70% per year. The lowest was -120.50% per year. And the median was -72.50% per year.

Competitive Comparison of Immix Biopharma's 3-Year EPS without NRI Growth Rate

For the Biotechnology subindustry, Immix Biopharma's 3-Year EPS without NRI Growth Rate, along with its competitors' market caps and 3-Year EPS without NRI Growth Rate data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Immix Biopharma's 3-Year EPS without NRI Growth Rate Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Immix Biopharma's 3-Year EPS without NRI Growth Rate distribution charts can be found below:

* The bar in red indicates where Immix Biopharma's 3-Year EPS without NRI Growth Rate falls into.

Save Embed

;

Save Embed

;

Immix Biopharma 3-Year EPS without NRI Growth Rate Calculation

This is the 3-year average growth rate of EPS without NRI. The growth rate is calculated using exponential compounding based on the latest four year annual data.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EPS without NRI growth rate.

Immix Biopharma (NAS:IMMX) 3-Year EPS without NRI Growth Rate Explanation

EPS without NRI is the amount of earnings without non-recurring items per outstanding share of the company's stock.

Earnings Per Share (EPS) is the single most important variable used by Wall Street in determining the earnings power of a company. But investors need to be aware that Earnings per Share can be easily manipulated by adjusting depreciation and amortization rate or non-recurring items. That's why GuruFocus lists Earnings per share without Non-Recurring Items, which better reflects the company's underlying performance.

Immix Biopharma 3-Year EPS without NRI Growth Rate Related Terms

Thank you for viewing the detailed overview of Immix Biopharma's 3-Year EPS without NRI Growth Rate provided by GuruFocus.com. Please click on the following links to see related term pages.

Immix Biopharma Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Immix Biopharma Inc (NAS:IMMX) » Definitions » 3-Year EPS without NRI Growth Rate

Comparable Companies

Traded in Other Exchanges

N/A

Address

11400 West Olympic Boulevard, Suite 200, Los Angeles, CA, USA, 90064

Website

https://www.immixbio.com

Immix Biopharma Inc is engaged in the discovery and development of novel cell therapies for hematologic malignancies (blood cancers) and other indications. It is a clinical-stage biopharmaceutical company developing a novel class of Tissue-Specific Therapeutics TM in oncology and inflammation. Its TME Normalization Technology allows drug candidates to circulate in the bloodstream, exit through tumor blood vessels and simultaneously attack all components of the TME. Its product candidates include CAR-T NXC-201 for autoimmune diseases, and IMX-110 for treatment of soft tissue sarcoma.

Executives

Jason Hsu	director	11400 WEST OLYMPIC BLVD., SUITE 200, LOS ANGELES CA 90064
Carey Ng	director	11400 WEST OLYMPIC BLVD., SUITE 200, LOS ANGELES CA 90064
Ilya M Rachman	director, officer: CEO and Chairman	11400 WEST OLYMPIC BLVD.,, SUITE 200, LOS ANGELES CA 90064
Gabriel S Morris	director, officer: Chief Financial Officer	11400 WEST OLYMPIC BLVD.,, SUITE 200, LOS ANGELES CA 90064
Helen C. Adams	director	15378 AVENUE OF SCIENCE, STE 100, SAN DIEGO CA 92128
Melissa Jane Buchan	director	1920 MAIN STREET, SUITE 500, IRVINE CA 92614
Magda Marquet	director	ALTHEADX INC., 3550 DUNHILL STREET, SAN DIEGO CA 92121
Yekaterina Chudnovsky	director, 10 percent owner	C/O ELICIO THERAPEUTICS, INC., 451 D STREET, 5TH FLOOR, SUITE 501, BOSTON MA 02210
Sean Senn	10 percent owner	11400 WEST OLYMPIC BLVD., SUITE 200, LOS ANGELES CA 90064
Vladimir P Torchilin	officer: Scientific Co-Founder	11400 WEST OLYMPIC BLVD.,, SUITE 200, LOS ANGELES CA 90064
Graham Ross	officer: CMO & Head of Clinical Dev.	11400 WEST OLYMPIC BLVD., SUITE 200, LOS ANGELES CA 90064